Harmony Biosciences Holdings, Inc.
HRMY
$29.17
$0.180.62%
| Weiss Ratings | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | B- | |||
| Rating Factors | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.21 | |||
| Price History | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.33% | |||
| 30-Day Total Return | -13.83% | |||
| 60-Day Total Return | -21.01% | |||
| 90-Day Total Return | -15.86% | |||
| Year to Date Total Return | -16.25% | |||
| 1-Year Total Return | -6.69% | |||
| 2-Year Total Return | -7.91% | |||
| 3-Year Total Return | -38.13% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -30.33% | |||
| 52-Week Low % Change | 9.52% | |||
| Price | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $41.61 | |||
| 52-Week Low Price | $26.47 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Oct 29, 2024 | |||
| Valuation | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.66B | |||
| Enterprise Value | 1.38B | |||
| Price/Earnings (TTM) | 11.56 | |||
| Earnings Per Share (TTM) | 2.51 | |||
| Earnings Per Share Growth | 18.49% | |||
| Price/Earnings To Growth | 0.63 | |||
| Price/Sales (TTM) | 2.36 | |||
| Price/Book (Q) | 2.51 | |||
| Enterprise Value/Revenue (TTM) | 1.93 | |||
| Price | $29.17 | |||
| Enterprise Value/EBITDA (TTM) | 6.40 | |||
| Enterprise Value/EBIT | 7.21 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 58.22M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 484 539 9800 | |||
| Address | 630 West Germantown Pike Plymouth Meeting, PA 19462 | |||
| Website | www.harmonybiosciences.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 26.69% | |||
| Profit Margin | 20.35% | |||
| Management Effectiveness | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 13.17% | |||
| Return on Equity | 25.84% | |||
| Income Statement | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 714.73M | |||
| Total Revenue (TTM) | 714.73M | |||
| Revenue Per Share | $12.28 | |||
| Gross Profit (TTM) | 557.92M | |||
| EBITDA (TTM) | 214.94M | |||
| EBIT (TTM) | 190.83M | |||
| Net Income (TTM) | 145.49M | |||
| Net Income Avl. to Common (TTM) | 145.49M | |||
| Total Revenue Growth (Q YOY) | 19.51% | |||
| Earnings Growth (Q YOY) | 85.95% | |||
| EPS Diluted (TTM) | 2.51 | |||
| EPS Diluted Growth (Q YOY) | 89.84% | |||
| Balance Sheet | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 467.19M | |||
| Cash Per Share (Q) | $8.02 | |||
| Total Current Assets (Q) | 579.25M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 659.16M | |||
| Current Ratio (Q) | 3.308 | |||
| Book Value Per Share (Q) | $11.53 | |||
| Total Assets (Q) | 999.20M | |||
| Total Current Liabilities (Q) | 175.08M | |||
| Total Debt (Q) | 181.41M | |||
| Total Liabilities (Q) | 340.05M | |||
| Total Common Equity (Q) | 659.16M | |||
| Cash Flow | HRMY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -67.48M | |||
| Cash from Financing (TTM) | -11.00M | |||
| Net Change in Cash (TTM) | 141.34M | |||
| Levered Free Cash Flow (TTM) | 143.91M | |||
| Cash from Operations (TTM) | 219.82M | |||
